Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

Withdrawn before enrolling · Not applicable

Conditions studied: Prostatic Hyperplasia

In brief

The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) at 12 months post prostatic artery embolization (PAE) with bland microspheres.

Key facts

Study ID

NCT03179228

Run by

John D Louie

People needed

0

Starts

2017-10-14

Expected to finish

2028-06-01

Last updated by the study team

2017-10-17

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Patient is aged 50 years or older.
• Patient has signed informed consent
• Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment
• Patient has a prostate size larger than 40g as measured by MRI or CT (if MR not possible)
• Patient has an IPSS score greater than or equal to 13
• Patient either:
• i. Refuses surgical treatment ii. Is considered high risk for surgical treatment
• Patient is either:
• i. Refractory to medical treatment ii. Contraindicated for medical treatment
• Patient must meet ONE of the following criteria:
• Baseline PSA ≤ 2.5ng/mL
• Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required)
• Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA < 25% of total PSA AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
• Baseline PSA >10 ng/mL AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
• Patient has a peak urine flow rate < 12ml/sec.

You may not qualify if…

• Active prostatitis or urinary tract infection
• History of prostate or bladder cancer, or currently being evaluated for cancer
• Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function.
• Urethral stricture, bladder neck contracture, other potentially confounding bladder pathology, bladder disease, or confounding urethral pathology
• Patient has taken beta blockers, antihistamines, anticonvulsants, or antispasomodics within 1 week of study treatment AND has not been on the same drug dosage for 6 months with a stable voiding pattern.
• Patient has taken antidepressant, anticholinergics, androgens or gonadotropin-releasing hormonal analogues within 2 months of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
• Patient has taken alpha blockers within 4 weeks of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
• Patient has taken 5-alpha reductase inhibitors within 3 months of study treatment AND has not been on the same drug for at least 6 months with a stable voiding pattern
• History of open prostate surgery, radiofrequency, or microwave therapy
• Previous open bladder or rectosigmoid colon surgery
• Acute urinary retention requiring an indwelling catheter
• Cystolithiasis within the past 3 months
• Coagulation disturbances not normalized by medical treatment
• Iodinated contrast allergy not controlled with 24-hour steroid preparation
• History of pelvic irradiation
• History of severe peripheral vascular disease or known major iliac arterial occlusive disease
• Interest in future fertility
• Significant cardiac or respiratory disease that the Investigator believes puts the patient at risk for a complication during the procedure
• Acute urinary retention requiring an indwelling catheter
• Life expectancy less than 6 months
• History of rectal disease
• Known immunosuppression either pathological or pharmacological
• Presence of collateral vessel pathways potentially endangering normal anatomy during embolization that cannot be bypassed with the microcatheter
• History of any illness or surgery that might confound the results of the study, by producing symptoms which may be confused with those of the disease process under consideration (e.g., Parkinson's, multiple Sclerosis), or which pose an additional risk to the patient.

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.